Global oncology company Novocure (NASDAQ: NVCR) announced on Wednesday that it has officially inaugurated its new global headquarters in Baar, Canton of Zug, Switzerland. This move supports the company's ongoing growth as it advances its mission to extend survival in aggressive cancers through its Tumor Treating Fields (TTFields) therapy.

Since opening its first Swiss office in 2013, Novocure has expanded its workforce in the Zurich area to over 200 employees. The new facility is designed with collaborative workspaces to enhance creativity and productivity, and incorporates advanced sustainable technologies such as a reversible air-to-water heat pump powered by rooftop solar panels.

Previously based in Root, Canton of Lucerne, Novocure's new headquarters reflects its commitment to environmental sustainability. The building utilises innovative solutions to reduce consumption and waste.

Novocure's TTFields therapy targets cancer cells through electric fields, sparing healthy cells. It can be combined with other cancer treatments like chemotherapy and radiotherapy, offering clinical versatility across a range of solid tumors.

Headquartered in Baar, Novocure also has US operations in Portsmouth, New Hampshire, as well as research facilities in Haifa, Israel. The company's products are approved for use in treating glioblastoma, non-small cell lung cancer and malignant pleural mesothelioma.